Education
About Us
Working with TipRanks
Follow Us
Cantargia AB (DE:7V3)
FRANKFURT:7V3
7V3 Stock Chart & Stats
€0.47
>-€0.01(-1.59%)
At close: 4:00 PM EST
€0.47
>-€0.01(-1.59%)
Day’s Range― - ―
52-Week Range€0.06 - €0.56
Previous CloseN/A
Volume0.00
Average Volume (3M)715.00
Market Cap
€119.36M
Enterprise Value€941.21M
Total Cash (Recent Filing)€339.14M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)10.1
Beta0.35
Next Earnings
Feb 20, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding248,611,650
10 Day Avg. Volume0
30 Day Avg. Volume715
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.67
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.32Price Target Upside180.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Nadunolimab Clinical Potential And DiagnosticNadunolimab's immune-priming mechanism and progress on an IL1RAP companion diagnostic support readiness for a first-line pancreatic cancer trial and create potential to expand use if clinical efficacy is shown.
Preclinical And Autoimmune ExpansionAdvancement of next-generation anti-IL1RAP antibodies and a bispecific autoimmune program targets markets with limited competition, offering multiple distinct value drivers beyond oncology.
Strategic Partnership And Non-dilutive FinancingAcquisition of the CAN10 program by a major pharmaceutical company validates the IL1RAP approach and provides non-dilutive financing plus milestone and royalty upside, reducing Cantargia's development burden and freeing capital for other programs.
Bears Say
Colorectal Immunotherapy ChallengeThe targeted colorectal cancer population has historically been non-responsive to immunotherapy, which raises the bar and increases the risk that nadunolimab will struggle to demonstrate meaningful clinical benefit in that cohort.
Investor Sentiment And Market ReactionNegative market reaction to clinical setbacks has pressured investor sentiment and could limit near-term stock recovery despite progress in other programs.
Triple-negative Breast Cancer Program FailureFinal survival results and the Phase 2 TRIFOUR outcome confirmed a lack of efficacy in triple-negative breast cancer, removing expected therapeutic value for that indication.
Cantargia AB News
7V3 FAQ
What was Cantargia AB’s price range in the past 12 months?
Cantargia AB lowest stock price was €0.06 and its highest was €0.56 in the past 12 months.
What is Cantargia AB’s market cap?
Cantargia AB’s market cap is €119.36M.
When is Cantargia AB’s upcoming earnings report date?
Cantargia AB’s upcoming earnings report date is Feb 20, 2026 which is in 8 days.
How were Cantargia AB’s earnings last quarter?
Cantargia AB released its earnings results on Nov 19, 2025. The company reported €0.101 earnings per share for the quarter, beating the consensus estimate of -€0.016 by €0.117.
Is Cantargia AB overvalued?
According to Wall Street analysts Cantargia AB’s price is currently Undervalued.
Does Cantargia AB pay dividends?
Cantargia AB does not currently pay dividends.
What is Cantargia AB’s EPS estimate?
Cantargia AB’s EPS estimate is -0.02.
How many shares outstanding does Cantargia AB have?
Cantargia AB has 248,611,650 shares outstanding.
What happened to Cantargia AB’s price movement after its last earnings report?
Cantargia AB reported an EPS of €0.101 in its last earnings report, beating expectations of -€0.016. Following the earnings report the stock price went down -0.707%.
Which hedge fund is a major shareholder of Cantargia AB?
Currently, no hedge funds are holding shares in DE:7V3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cantargia AB
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.
7V3 Stock 12 Month Forecast
Average Price Target
€1.32
▲(180.85% Upside)
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
―
Guard Therapeutics International AB
―
Immunicum AB
―